Alirocumab (anti-PCSK9)

Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.

Alirocumab (anti-PCSK9)

Click to purchase the isotype control of Alirocumab (anti-PCSK9)

Purity & Quality Control

Batch: A204701 Purity: 98% Protein concentration: 4.3mg/ml Endotoxin Level: <1 EU/mg
98

Choose Selective PCSK9 Inhibitors

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.

Product Details

CAS No. 1245916-14-6
Molecular Weight 150 kDa
Isotype human IGg1, κ
Application Alirocumab (anti-PCSK9)
Source CHO
Purification Protein G
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Alirocumab (anti-PCSK9) | Alirocumab (anti-PCSK9) supplier | purchase Alirocumab (anti-PCSK9) | Alirocumab (anti-PCSK9) cost | Alirocumab (anti-PCSK9) manufacturer | order Alirocumab (anti-PCSK9) | Alirocumab (anti-PCSK9) distributor